This ‘Pancreatic Cancer - Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the pancreatic cancer historical and forecasted epidemiology as well as the pancreatic cancer market trends in the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The pancreatic cancer market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM pancreatic cancer market size. The report also covers current pancreatic cancer treatment practice, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Pancreatic cancer occurs when cells in the pancreas develop changes (mutations) in their DNA. A cell's DNA contains the instructions that tell a cell what to do. These mutations tell the cells to grow uncontrollably and to continue living after normal cells would die. These accumulating cells can form a tumor. When left untreated, pancreatic cancer cells can spread to nearby organs, blood vessels, and distant body parts.
Multiple biomarkers based on mutation panels, antibodies, circulating DNA, microRNAs, proteins, metabolites, methylated DNA, and exosomes have been tested for pancreatic cancer screening; however, they suffer from a lack of application in longitudinal screening of asymptomatic individuals and are still not ready for clinical use, except for one. Carbohydrate antigen 19-9 (CA 19-9) is the only tumor marker approved by the US Food and Drug Administration (FDA) and used for treatment monitoring in pancreatic cancer.
Five types of standard treatment that are used for pancreatic cancer are as follows.
Surgery
Surgery for pancreatic cancer includes removing all or part of the pancreas, depending on the location and size of the tumor in the pancreas. An area of healthy tissue around the tumor is also often removed. This is called a margin. A goal of surgery is to have “clear margins” or “negative margins,” which means that there are no cancer cells on the edges of the healthy tissue removed.
About 20% of people diagnosed with pancreatic cancer can have surgery because most pancreatic cancers are found after the disease has already spread. Surgery for pancreatic cancer may be combined with systemic therapy and/or radiation therapy. Typically, these additional treatments are given after surgery, which is called adjuvant therapy. However, systemic therapy and/or radiation therapy may sometimes be used before surgery to shrink a tumor, and this is called neoadjuvant therapy or preoperative therapy. After neoadjuvant therapy, the tumor is re-staged before planning surgery. Re-staging is usually done with another CT scan to look at the change in tumor size and what nearby structures and blood vessels it is affecting.
Pancreatic ductal adenocarcinoma (PDAC) patients constitute the major portion of the pancreatic cancer-affected population. Although advancements have been made in operative techniques and chemotherapy with time, survival rates for pancreatic cancer patients remain low. Diagnosis of pancreatic cancer in the late or advance stage i.e. Stage III, and Stage IV is the main reason for low survival. Many patients are not eligible for the treatment by this time, and in most patients, the tumor has become metastatic. Surgery can be efficiently utilized in patients with cancer in localized or regional states, and the proportion of such patients is generally low at the time of diagnosis. In the study conducted by Kasumova et al. (2017), pancreatic cancer was diagnosed in Stage I/II in only around 35% of the patients, whereas, in the remaining patients, pancreatic cancer is diagnosed at Stage III/IV. Among the patients who had disease diagnosed in Stage I/II, only 54.5% of Stage I and 43.4% of Stage II patients had undergone tumor resection. In this study, it was also reported that there had been an increase in the use of neoadjuvant therapy in Stage I and II diagnosed pancreatic cancer patients. In the case of the patients having pancreatic cancer in the advanced stage, only 68.4% and 56.9% of patients with Stage III and IV disease, respectively, received chemotherapy and/or radiation therapy.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The pancreatic cancer market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM pancreatic cancer market size. The report also covers current pancreatic cancer treatment practice, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- The United States
- EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Pancreatic Cancer Disease Understanding and Treatment
Pancreatic Cancer Overview
Pancreatic cancer begins in the tissues of the pancreas - an organ in the abdomen that lies behind the lower part of the stomach. The pancreas release enzymes that aid digestion and produces hormones that help manage blood sugar. Pancreatic cancer is a disease in which malignant (cancer) cells form in the tissues of the pancreas. Several types of growth can occur in the pancreas, including cancerous and noncancerous tumors. The most common type of cancer that forms in the pancreas begins in the cells that line the ducts that carry digestive enzymes out of the pancreas (pancreatic ductal adenocarcinoma). Pancreatic cancer is seldom detected at its early stages when it is most curable, and this is because it often does not cause symptoms until after it has spread to other organs. Pancreatic cancer treatment options are chosen based on the extent of the cancer. Options may include surgery, chemotherapy, radiation therapy, or a combination of these.Pancreatic cancer occurs when cells in the pancreas develop changes (mutations) in their DNA. A cell's DNA contains the instructions that tell a cell what to do. These mutations tell the cells to grow uncontrollably and to continue living after normal cells would die. These accumulating cells can form a tumor. When left untreated, pancreatic cancer cells can spread to nearby organs, blood vessels, and distant body parts.
Pancreatic Cancer Diagnosis
Pancreatic cancer is difficult to diagnose because the symptoms of pancreatic cancer are often mistaken for those of other illnesses, such as irritable bowel syndrome. It may go undetected until it's advanced. By the time symptoms occur, diagnosing pancreatic cancer is usually relatively straightforward; unfortunately, a cure is rarely possible. Diagnosing pancreatic cancer usually happens when someone comes to the doctor after experiencing weeks or months of symptoms. Pancreatic cancer symptoms frequently include abdominal pain, weight loss, itching, or jaundice (yellow skin). It is crucially important that patients are diagnosed as early as possible because early diagnosis can increase the chance of a patient having surgery to remove the tumor - currently the only potential cure. At present, only around 10% of cases are eligible for resectional surgery.Multiple biomarkers based on mutation panels, antibodies, circulating DNA, microRNAs, proteins, metabolites, methylated DNA, and exosomes have been tested for pancreatic cancer screening; however, they suffer from a lack of application in longitudinal screening of asymptomatic individuals and are still not ready for clinical use, except for one. Carbohydrate antigen 19-9 (CA 19-9) is the only tumor marker approved by the US Food and Drug Administration (FDA) and used for treatment monitoring in pancreatic cancer.
Pancreatic Cancer Treatment
For the treatment of pancreatic cancer, the following groups are used to plan the treatment.- Resectable pancreatic cancer - Resectable pancreatic cancer can be removed by surgery because it has not grown into important blood vessels near the tumor.
- Borderline resectable pancreatic cancer - Borderline resectable pancreatic cancer has grown into a major blood vessel or nearby tissue or organs. It may be possible to remove the tumor, but there is a high risk that all of the cancer cells will not be removed with surgery.
- Locally advanced pancreatic cancer - Locally advanced pancreatic cancer has grown into or close to nearby lymph nodes or blood vessels, so surgery cannot completely remove cancer.
- Metastatic pancreatic cancer - Metastatic pancreatic cancer has spread to other organs, so surgery cannot completely remove cancer.
- Recurrent pancreatic cancer - Recurrent pancreatic cancer has recurred (come back) after it has been treated. Cancer may come back in the pancreas or in other parts of the body.
Five types of standard treatment that are used for pancreatic cancer are as follows.
Surgery
Surgery for pancreatic cancer includes removing all or part of the pancreas, depending on the location and size of the tumor in the pancreas. An area of healthy tissue around the tumor is also often removed. This is called a margin. A goal of surgery is to have “clear margins” or “negative margins,” which means that there are no cancer cells on the edges of the healthy tissue removed.
About 20% of people diagnosed with pancreatic cancer can have surgery because most pancreatic cancers are found after the disease has already spread. Surgery for pancreatic cancer may be combined with systemic therapy and/or radiation therapy. Typically, these additional treatments are given after surgery, which is called adjuvant therapy. However, systemic therapy and/or radiation therapy may sometimes be used before surgery to shrink a tumor, and this is called neoadjuvant therapy or preoperative therapy. After neoadjuvant therapy, the tumor is re-staged before planning surgery. Re-staging is usually done with another CT scan to look at the change in tumor size and what nearby structures and blood vessels it is affecting.
Pancreatic Cancer Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Pancreatic Cancer, Molecular Alteration-specific Incident Cases of Pancreatic Cancer, and Stage-specific Incident Cases of Pancreatic Cancer scenario in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.Key Findings
- In 2021, the total incident cases of pancreatic cancer in the 7MM countries were 175,767 cases, and these cases are anticipated to increase during the study period.
- Among the European countries, Germany had the highest incident cases of pancreatic cancer in 2021, i.e., 21,859 cases, followed by France which had 14,989 incident cases in 2021. On the other hand, Spain had the lowest incident cases of pancreatic cancer, i.e. 8,566 cases in 2021. Japan had 43,170 incident cases of pancreatic cancer in 2021.
- In terms of stage-specific incident cases, maximum number of patients were observed for distant pancreatic cancer. This was followed by regional and localized pancreatic cancer.
- According to the publisher, majority of pancreatic cancer cases are caused by KRAS2 mutation followed by TP53 and SMAD4/DPC4 mutations. Least number of incident cases were observed for pancreatic cancer associated with NTRK mutation.
Pancreatic Cancer Epidemiology
The epidemiology segment provides the pancreatic cancer epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.Pancreatic Cancer Drug Chapters
Pancreatic Cancer Emerging Drugs
OSE2101: OSE Immunotherapeutics
OSE2101 is a therapeutic neo-epitope-based vaccine. It is a proprietary combination of nine optimized neo-epitopes, selected and optimized from five tumoral antigens to activate specifically T-cells, plus one epitope giving universal helper T-cell response targeting T-cell activation. Phase II study TEDOPAM compares Tedopi in combination with FOLFIRI chemotherapy versus FOLFIRI, in maintenance treatment after treatment with FOLFIRINOX. The primary endpoint of the trial is the 1-year survival rate.Motixafortide (BL-8040): BioLineRx
Motixafortide (formerly known as BL-8040/BKT140) is a novel selective inhibitor of the CXCR4 chemokine receptor. CXCR4 is a well-validated therapeutic target involved in the mobilization and trafficking of hematopoietic stem cells, immune cells, and cancer cells from the bone marrow and the lymph nodes to the peripheral blood. Motixafortide is being developed as a platform for several indications, including mobilization of hematopoietic stem cells (HSCs) for autologous transplantations, treatment of solid tumors, and other hematological malignancies.Anktiva (N-803): ImmunityBio
The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of the natural killer (NK) and T-cells. N-803 is a novel IL-15 superagonist complex consisting of an IL-15 mutant (IL-15N72D) bound to an IL-15 receptor α/IgG1 Fc fusion protein. Its mechanism of action is direct specific stimulation of CD8 + T-cells and NK cells through beta-gamma T cell receptor binding (not alpha) while avoiding T-reg stimulation. N-803 has improved pharmacokinetic properties, longer persistence in lymphoid tissues, and enhanced anti-tumor activity compared to native, non-complexed IL-15 in vivo.SBP-101: Panbela Therapeutics
SBP-101 is a proprietary polyamine analog designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors. Laboratory studies suggest the primary mechanism of action of SBP-101 is driven by its enhanced uptake in pancreatic cancer cells and, potentially, other cancer cell types, resulting in disruption of normal polyamine metabolism. SBP-101 is also taken up preferentially by the exocrine pancreas, the liver, and kidneys. Importantly, pancreatic islet cells, which secrete insulin and are structurally and functionally dissimilar to acinar cells, are not impacted by SBP-101.Pancreatic Cancer Market Outlook
Pancreatic cancer is enlisted as one of the most common cancers and the seventh-highest cause of cancer mortality worldwide. The incidence of pancreatic cancer is increasing in the Western world. The incidence of pancreatic adenocarcinoma is rising in the developed world, and modifiable lifestyle factors such as alcohol and obesity may play an essential role. The five-year survival from this disease is as low as 2% in some countries, despite improvements in surgical technique, chemotherapy regimens, and the introduction of neoadjuvant chemoradiotherapy. Currently, the main therapeutic approach for pancreatic cancer patients is majorly based on chemotherapy.Pancreatic ductal adenocarcinoma (PDAC) patients constitute the major portion of the pancreatic cancer-affected population. Although advancements have been made in operative techniques and chemotherapy with time, survival rates for pancreatic cancer patients remain low. Diagnosis of pancreatic cancer in the late or advance stage i.e. Stage III, and Stage IV is the main reason for low survival. Many patients are not eligible for the treatment by this time, and in most patients, the tumor has become metastatic. Surgery can be efficiently utilized in patients with cancer in localized or regional states, and the proportion of such patients is generally low at the time of diagnosis. In the study conducted by Kasumova et al. (2017), pancreatic cancer was diagnosed in Stage I/II in only around 35% of the patients, whereas, in the remaining patients, pancreatic cancer is diagnosed at Stage III/IV. Among the patients who had disease diagnosed in Stage I/II, only 54.5% of Stage I and 43.4% of Stage II patients had undergone tumor resection. In this study, it was also reported that there had been an increase in the use of neoadjuvant therapy in Stage I and II diagnosed pancreatic cancer patients. In the case of the patients having pancreatic cancer in the advanced stage, only 68.4% and 56.9% of patients with Stage III and IV disease, respectively, received chemotherapy and/or radiation therapy.
Key Findings
- The market size of pancreatic cancer in the 7MM was observed to be of USD 1,649 million in 2021.
- In 2021, the market size of pancreatic cancer in the US was of USD 858 million. Among the EU-5 countries, Germany had the highest market size for pancreatic cancer in 2021, i.e., USD 165 million. The lowest market size was estimated in Spain with USD 61 million in 2021.
- In Japan, the market size of pancreatic cancer was observed to be of USD 270 million in 2021.
- The United States and Japan account for 52% and 16% respectively of the total market size among the 7MM countries in 2021.
- Among all the available therapies, in 2021, the highest market was captured by FOLFIRINOX with a market size of USD 569 million, whereas the minimum market capture was by S1 combination therapy in the 7MM.
- The overall market size of gemcitabine (including monotherapy, and all combinations) in the pancreatic cancer space was of USD 625 million in 2021.
The United States Market Outlook
This section provides the total pancreatic cancer market size and market size by therapies in the United States.EU-5 Market Outlook
The total pancreatic cancer market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.Japan Market Outlook
The total pancreatic cancer market size and market size by therapies in Japan are provided.Pancreatic Cancer Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the pancreatic cancer market or expected to get launched in the market during the study period 2019-2032. The analysis covers the pancreatic cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Pancreatic Cancer Development Activities
The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyzes key players involved in developing targeted therapeutics.Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for pancreatic cancer emerging therapies.Reimbursement Scenario in Pancreatic Cancer
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.Competitive Intelligence Analysis
The publisher performs competitive market Intelligence analysis of the pancreatic cancer market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.Scope of the Report
- The report covers the descriptive overview of pancreatic cancer, explaining its causes, symptoms, pathophysiology, genetic basis, diagnosis, and currently available therapies.
- Comprehensive insight has been provided into the pancreatic cancer epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for pancreatic cancer is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of the pancreatic cancer market; historical and forecasted is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM pancreatic cancer market.
Report Highlights
- The robust pipeline with novel MOA and oral ROA, increasing incidence, and effectiveness of drugs will positively drive the pancreatic cancer market.
- The companies and academics are working to assess challenges and seek opportunities that could influence pancreatic cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for pancreatic cancer. The launch of emerging therapies will significantly impact the pancreatic cancer market.
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Pancreatic Cancer Report Insights
- Patient Population
- Therapeutic Approaches
- Pancreatic Cancer Pipeline Analysis
- Pancreatic Cancer Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Pancreatic Cancer Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Pancreatic Cancer Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Pancreatic Cancer Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- SWOT analysis
Key Questions Answered
Market Insights:
- What was the pancreatic cancer market share (%) distribution in 2019 and how it would look like in 2032?
- What would be the pancreatic cancer total market size as well as market size by therapies across the 7MM during the forecast period (2022-2032)?
- What are the key findings pertaining to the market across the 7MM and which country will have the largest pancreatic cancer market size during the forecast period (2022-2032)?
- At what CAGR, the pancreatic cancer market is expected to grow at the 7MM level during the forecast period (2022-2032)?
- What would be the pancreatic cancer market outlook across the 7MM during the forecast period (2022-2032)?
- What would be the pancreatic cancer market growth till 2032 and what will be the resultant market size in the year 2032?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What are the disease risk, burdens, and unmet needs of pancreatic cancer?
- What is the historical pancreatic cancer patient pool in the United States, EU-5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of pancreatic cancer at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to pancreatic cancer?
- Out of the above-mentioned countries, which country would have the highest population of pancreatic cancer during the forecast period (2022-2032)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the treatment of pancreatic cancer along with the approved therapy?
- What are the current treatment guidelines for the treatment of pancreatic cancer?
- What are the pancreatic cancer marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
- How many companies are developing therapies for the treatment of pancreatic cancer?
- How many emerging therapies are in the mid-stage and late stages of development for the treatment of pancreatic cancer?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the pancreatic cancer therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for pancreatic cancer and their status?
- What are the key designations that have been granted for the emerging therapies for pancreatic cancer?
- What are the 7MM historical and forecasted market of pancreatic cancer?
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving pancreatic cancer.
- To understand the future market competition in the pancreatic cancer market and an insightful review of the market.
- Organize sales and marketing efforts by identifying the best opportunities for pancreatic cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for the pancreatic cancer market.
- To understand the future market competition in the pancreatic cancer market.
Table of Contents
1. Key Insights2. Report Introduction4. Pancreatic Cancer - Future Prospects5. Executive Summary of Pancreatic Cancer6. Key Events9. Methodology11. Patient Journey16. KOL Views17. SWOT Analysis18. Unmet Needs20. Publisher Capabilities21. Disclaimer22. About the Publisher
3. Pancreatic Cancer-Market Overview at a Glance
7. Disease Background and Overview
8. Treatment and Management
10. Epidemiology and Patient Population
12. Marketed Products
13. Emerging Therapies
14. Pancreatic Cancer: Seven Major Market Analysis
15. Market Access and Reimbursement
19. Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca
- Merck Sharp & Dohme LLC
- Bayer
- Roche
- Celgene
- Bristol Myers Squibb
- BioLineRx
- Alligator Bioscience
- Bellicum Pharmaceuticals
- OSE Immunotherapeutics
- Actuate Therapeutics
- FibroGen
- NeoImmuneTech
- NOXXON Pharma
- Silenseed Ltd.
- Amgen
- NGM Biopharmaceuticals
- Merus
- Mirati Therapeutics
- Rexahn Pharmaceuticals
- Ocuphire Pharma
- Processa Pharmaceuticals
- ImmunityBio
- Berg
- Panbela Therapeutics
- GlaxoSmithKline
- Eleison Pharmaceuticals
- Molecular Templates
- Lokon Pharma AB
- Cantargia AB
